Clinical Trial Update: Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma [Phase 1]

View source ↗

Summary

Phase 1 trial of Poly-ICLC (Hiltonol) vaccine in malignant pleural mesothelioma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Hiltonol (Poly-ICLC)

Snippet

Sponsor: Oncovir, Inc. | Conditions: Malignant Pleural Mesothelioma | Phase 1 | Status: COMPLETED